IPO
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
The Fund has now invested a total of USD 30 million in six companies
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
Revenue and EBITDA for full year 2019 expected to be ahead of market expectations
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, announces the results of its rights issue for a limited amount of € 521 K.
Turku, Finland, July 19th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.
Assertio Therapeutics, Inc. announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets.
Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
PRESS RELEASES